Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - oxaliplatin - solution for infusion - 5mg/1ml

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - oxaliplatin - solution for infusion - 5mg/1ml

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - oxaliplatin - solution for infusion - 5mg/1ml

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - oxaliplatin - solution for infusion - 5mg/1ml

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - oxaliplatin - solution for infusion - 5mg/1ml

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

medac uk - oxaliplatin - solution for infusion - 5mg/1ml

Ierland - Engels - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - oxaliplatin - concentrate for solution for infusion - 5 milligram(s)/millilitre - platinum compounds; oxaliplatin

Israël - Engels - Ministry of Health

vitamed pharmaceutical industries ltd - oxaliplatin - concentrate for solution for infusion - oxaliplatin 5 mg / 1 ml - oxaliplatin - oxaliplatin in combination with 5- fluorouracil (5-fu) and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of primary tumour. - treatment of metastatic colorectal cancer.oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

Singapore - Engels - HSA (Health Sciences Authority)

accord healthcare private limited - oxaliplatin - infusion, solution concentrate - oxaliplatin 5 mg

Singapore - Engels - HSA (Health Sciences Authority)

advagen pte. ltd. - oxaliplatin - infusion, solution concentrate - oxaliplatin 5mg/ml